Roving Reporter Asks: Where Do You See the Most Progress in CGT Manufacturing and Scalability?
-
May 6, 2026
Original Source(s)
Related Content
Abiraterone Plus Olaparib Shows ‘Remarkable’ Survival in <em>BRCA/ATM</em>-Mutated Metastatic Castration-Resistant Prostate Cancer
Updated results from the phase II BRCAAway trial showed that first-line treatment with abiraterone and prednisone plus olaparib resulted in a median overall survival of more than 5 years in patients w...
May 5, 2026
-
15 min
Integrated Molecular Analysis Identifies Determinants of Outcomes in <em>TP53</em>-Mutated DLBCL
In a study reported in the Journal of Clinical Oncology, Uppal et al identified factors associated with poorer outcomes in patients with TP53-mutated diffuse large B-cell lymphoma (DLBCL).
May 5, 2026
-
2 min
Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases
In a French phase II trial (PACHA-01) reported in the Journal of Clinical Oncology, Gelli et al found that adjuvant hepatic infusion of oxaliplatin improved hepatic recurrence–free survival vs intrave...
May 5, 2026
-
3 min
